1. Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma. (1st January 2020) Authors: Drakaki, Alexandra; Dhillon, Preet K; Wakelee, Heather; Chui, Stephen Y; Shim, Jinjoo; Kent, Matthew; Degaonkar, Viraj; Hoang, Tien; McNally, Virginia; Luhn, Patricia; Gutzmer, Ralf Journal: Oncoimmunology Issue: Volume 9:Number 1(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study. (1st February 2021) Authors: Emens, Leisha A; Molinero, Luciana; Loi, Sherene; Rugo, Hope S; Schneeweiss, Andreas; Diéras, Véronique; Iwata, Hiroji; Barrios, Carlos H; Nechaeva, Marina; Nguyen-Duc, Anh; Chui, Stephen Y; Husain, Amreen; Winer, Eric P; Adams, Sylvia; Schmid, Peter Journal: Journal of the National Cancer Institute Issue: Volume 113:Number 8(2021) Page Start: 1005 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Issue 1 (January 2020) Authors: Schmid, Peter; Rugo, Hope S; Adams, Sylvia; Schneeweiss, Andreas; Barrios, Carlos H; Iwata, Hiroji; Diéras, Véronique; Henschel, Volkmar; Molinero, Luciana; Chui, Stephen Y; Maiya, Vidya; Husain, Amreen; Winer, Eric P; Loi, Sherene; Emens, Leisha A Journal: Lancet oncology Issue: Volume 21:Issue 1(2020) Page Start: 44 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Issue 10257 (10th October 2020) Authors: Mittendorf, Elizabeth A; Zhang, Hong; Barrios, Carlos H; Saji, Shigehira; Jung, Kyung Hae; Hegg, Roberto; Koehler, Andreas; Sohn, Joohyuk; Iwata, Hiroji; Telli, Melinda L; Ferrario, Cristiano; Punie, Kevin; Penault-Llorca, Frédérique; Patel, Shilpen; Duc, Anh Nguyen; Liste-Hermoso, Mario; Maiya, ... Journal: Lancet Issue: Volume 396:Issue 10257(2020) Page Start: 1090 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel–Treated Advanced Triple-Negative Breast Cancer. (7th June 2021) Authors: Rugo, Hope S; Loi, Sherene; Adams, Sylvia; Schmid, Peter; Schneeweiss, Andreas; Barrios, Carlos H; Iwata, Hiroji; Diéras, Véronique; Winer, Eric P; Kockx, Mark M; Peeters, Dieter; Chui, Stephen Y; Lin, Jennifer C; Nguyen-Duc, Anh; Viale, Giuseppe; Molinero, Luciana; Emens, Leisha A Journal: Journal of the National Cancer Institute Issue: Volume 113:Number 12(2021) Page Start: 1733 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗